Omeicos Therapeutics GmbH   Report issue

For profit Phase 2 Phase 4
Founded: Berlin Germany (2013)

Organization Overview

First Clinical Trial
2017
NCT03078738
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Managing Director | Omeicos Therapeutics GmbH

Active Ingredients

Drugs in Phase 4 Trials (1)

cariprazine (vraylar) (1 trial)

Drugs in Phase 2 Trials (1)

omt-28 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2